International Clinical Trial: Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204639) titled 'Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Clarent Biopharma, Inc.

Condition: Psoriasis

Intervention: Drug: RAP103 400mg single dose Drug: RAP103 200mg BID Drug: Placebo for RAP400

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 1, 2025

Target Sample Size:...